TILT Biotherapeutics Ltd.
Haartmaninkatu 3, 4th Floor
C-wing
Helsinki
00290
Website: http://tiltbio.com/
Email: akseli@tiltbio.com
About TILT Biotherapeutics Ltd.
TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of solid tumors as currently achieved for CD19+ hematological tumors.YEAR FOUNDED:
2013
LEADERSHIP:
Founder and CEO: Akseli Hemminki
4 articles with TILT Biotherapeutics Ltd.
-
TILT Holdings Announces CMW Media as Strategic Communications Firm
7/31/2019
Engagement highlights TILT’s renewed focus on corporate communication
-
TILT Biotherapeutics Initiates Collaboration With Merck KGaA, Darmstadt, Germany and Pfizer Investigating the Combination of Oncolytic Virus, TILT-123, And Anti-PDL1 Antibody, Avelumab
6/25/2019
Agreement to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities.
-
TILT Biotherapeutics Wins a Grant from European Commission for a Phase 1 Clinical Trial
6/4/2018
TILT Biotherapeutics Ltd has won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument.
-
TILT Biotherapeutics Secures $10.6 Million for Viral Cancer T-Cell Immunotherapy
12/14/2016